| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology's (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona.
Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, including a product theater presentation highlighting VOQUEZNA® (vonoprazan) tablets as an approved treatment for Gastroesophageal Reflux Disease (GERD) and a prominent presence on the exhibit floor.
"We are excited to build on the growing momentum for VOQUEZNA in the treatment of GERD by connecting with the GI community at ACG," said Steve Basta, President and Chief Executive Officer of Phathom. "Meetings like ACG provide an opportunity to share clinical insights, engage with experts, and reinforce our commitment to improving outcomes for patients with GI disorders."
Posted In: PHAT
